The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Impact of genomic alterations on outcomes in patients with metastatic castration resistant prostate cancer (mCRPC) treated with Lu-177 radioligand therapy (RLT).
 
Cameron Chalker
Consulting or Advisory Role - Johnson & Johnson
 
Colin Bergstrom
No Relationships to Disclose
 
Joseph Allen
No Relationships to Disclose
 
Burcak Yilmaz
No Relationships to Disclose
 
Hong Song
Consulting or Advisory Role - Lanth; Lanth
Research Funding - Clarity Pharmaceuticals (Inst)
 
Ali Khaki
Consulting or Advisory Role - Gilead Sciences (Inst)
Research Funding - 23andMe (Inst); Acrivon Therapeutics (Inst); Janssen Oncology (Inst); Pfizer (Inst)
(OPTIONAL) Uncompensated Relationships - Janssen; Pfizer/Astellas
 
Alexandra Sokolova
No Relationships to Disclose